A Michigan overview of physician-supervised GLP-1 treatment through Astra, including local access context and the cities we cover. Every statistic on this page links to its source.
36.1% of Michigan adults had obesity in 2024 (95% CI 34.8–37.5%, n=10,330 adults surveyed) 2 — up from 35.4% in 2023, a continued year-over-year rise 3. Michigan's population was 10,140,459 in the Vintage 2024 estimates 4.
Michigan is one of the states that does not slam the door on weight-loss drugs. It puts a prior-authorization gate in front of them instead, and the exact height of that gate is set outside the state's own manual.
Michigan Medicaid does not categorically exclude weight-loss drugs. The Pharmacy Provider Manual's noncovered-drugs list (Section 6) excludes only "agents used for anorexia" and "agents used for weight gain" — anti-obesity agents are conspicuously absent from it. Instead, Section 8.5.B ("Anti-Obesity," revised April 1, 2026) requires prior authorization for the drug class covering GLP-1s such as Wegovy, Zepbound, and Saxenda when prescribed for chronic weight management 1.
That PA requirement applies across Medicaid fee-for-service, the Healthy Michigan Plan (the state's ACA expansion population), CSHCS, and MOMS. Most beneficiaries are actually enrolled in a Medicaid Health Plan (managed care) rather than FFS; there, the statewide MHP Common Formulary sets a floor plans cannot go below — a plan may be less restrictive, never more (Section 1.7) 1.
Net effect: Michigan does not statutorily bar GLP-1 obesity coverage the way some states do, but access runs through a prior-authorization gate. The exact clinical bar — BMI cutoff, required comorbidities, step therapy, which brands sit on the preferred drug list — is published by the state's pharmacy benefits administrator, Prime Therapeutics State Government Solutions, LLC, on its Michigan Medicaid provider portal. That portal is a JavaScript-rendered system this research pass could not open, so treat "covered with PA" as confirmed and the specific clinical criteria as an open item — beneficiaries should check directly with their plan 1.
A PA gate means some Michigan patients wait on a determination and others never clear it. Cash pricing is what sits on the other side.
Astra's price in Michigan is the same as everywhere else we operate: compounded semaglutide from $68 per month and compounded tirzepatide from $118 per month on 12-month plans ($816 and $1,416 billed annually), the same price at every dose. There is no Michigan-specific discount or markup.
Median household income in Michigan is $72,389 6 and roughly 5.1% of residents are uninsured 5, both ACS 2024 1-year estimates.
HRSA counts 606 active Primary Care Health Professional Shortage Area designations statewide (pull dated Aug 27, 2026) — a mix of geographic-area, population-group, and single-facility designations 7. These overlap the same residents, so HRSA's data cannot be summed to a clean population-affected figure; only the designation count is reportable.
Specialist access for weight management thins out fast outside Michigan's larger metros, which is precisely where a video visit substitutes for a drive.
Michigan permits telehealth prescribing of non-controlled medications — GLP-1s among them — under its Public Health Code, administered by the Department of Licensing and Regulatory Affairs (LARA). [TODO: this research pass did not verify the exact statutory telehealth-prescribing citation or locate a confirmed LARA / Board of Medicine reference page; do not publish this section's outbound link until that's checked.]
Astra is licensed to treat patients in all 50 states, including all of Michigan — not only the three cities with their own pages.
Astra treats patients in Michigan through state-licensed physicians.
Ann Arbor, Grand Rapids, and Lansing pages carry local clinic pricing and specialist access.
Yes, with prior authorization. Michigan's Medicaid Pharmacy Provider Manual (Section 8.5.B, revised April 1, 2026) requires PA for anti-obesity drugs — the category covering GLP-1s like Wegovy, Zepbound, and Saxenda when prescribed for chronic weight management — but does not list weight-loss agents among its categorical exclusions (Section 6). This holds across Medicaid FFS, the Healthy Michigan Plan, CSHCS, and MOMS. The exact clinical bar for approval (BMI threshold, required comorbidities, step therapy) is set by the state's pharmacy benefits administrator and wasn't independently verifiable for this page — check directly with your plan before assuming coverage.
No — and that's by design. Astra charges the same national price everywhere it operates: $68/month for semaglutide and $118/month for tirzepatide, both on 12-month plans ($816 and $1,416 billed annually). There's no Michigan-specific discount or markup. Local clinics do set their own prices, and those vary by city — see the Ann Arbor, Grand Rapids, and Lansing pages for what's actually being charged in those markets.
36.1% of Michigan adults had obesity in 2024 (95% CI 34.8–37.5%, based on a sample of 10,330 adults), per the CDC's Behavioral Risk Factor Surveillance System. That's up from 35.4% in 2023, continuing a year-over-year rise.
Yes. Michigan permits telehealth prescribing of medications like GLP-1s under state law, administered by the Department of Licensing and Regulatory Affairs. GLP-1s aren't controlled substances, so they don't carry the extra restrictions telehealth rules place on controlled drugs.
All of Michigan. Astra is licensed in all 50 states, so residents anywhere in the state — not only Ann Arbor, Grand Rapids, or Lansing — can get care through telehealth. That matters here: HRSA counts 606 active Primary Care Health Professional Shortage Area designations across Michigan, and specialist access for weight management thins out fast outside the state's larger metros.
Last reviewed:
Educational information, not medical advice. Treatment requires evaluation by a licensed physician.